Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.50 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497368 | 1.00 | GPBAR1 (0.54) | GPBAR1NR1H4NR3C1SHBGMEN1 | |
| SCHEMBL7861033 | 0.81 | NR3C1 (0.63) | GPBAR1NR1H4NR3C1SHBGMEN1 | |
| SCHEMBL1143644 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL4327037 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL4304678 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL23866991 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL7177280 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL1419267 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL1143645 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA | |
| SCHEMBL3362972 | 0.80 | SHBG (0.76) | GPBAR1NR1H4NR3C1SHBGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040116359-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-03-04 | — | — | US | disclosed |
| US-6667299-B1 | 16-alpha-bromo-3-beta-hydroxy-5-alpha-androstan-17-one hemihydrate; 16-alpha-bromoepiandrosterone; steroid; immune modulator | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | GPBAR1 160/4885NR1H4 76/4885NR3C1 20/4885 |
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | GPBAR1 205/4885NR1H4 99/4885NR3C1 15/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | GPBAR1 331/4885NR1H4 415/4885NR3C1 43/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | GPBAR1 386/4885NR1H4 320/4885NR3C1 31/4885 |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | HSD3B1, IL4, HSD17B7 | GPBAR1 313/4885NR1H4 41/4885NR3C1 22/4885 |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | GPBAR1 199/4885NR1H4 66/4885NR3C1 18/4885 |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | HSD3B1, HSD3B2, HSD17B7 | GPBAR1 379/4885NR1H4 56/4885NR3C1 23/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | GPBAR1 360/4885NR1H4 395/4885NR3C1 10/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | GPBAR1 246/4885NR1H4 112/4885NR3C1 17/4885 |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | GPBAR1 360/4885NR1H4 395/4885NR3C1 10/4885 |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | GPBAR1 199/4885NR1H4 66/4885NR3C1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.